POS0516 Applicability of the phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab In SYstemic Sclerosis) inclusion criteria to the general SSc population – a study from the EUSTAR cohort

Kaye, E., Osborne, T., Thornton, L. et al. (4 more authors) (2025) POS0516 Applicability of the phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab In SYstemic Sclerosis) inclusion criteria to the general SSc population – a study from the EUSTAR cohort. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. BMJ Publishing Group , p. 730.

Metadata

Item Type: Proceedings Paper
Authors/Creators:
Dates:
  • Accepted: 26 March 2025
  • Published: June 2025
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 18 Jul 2025 13:34
Last Modified: 18 Jul 2025 13:34
Status: Published
Publisher: BMJ Publishing Group
Identification Number: 10.1016/j.ard.2025.05.898
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)